Reuters clears first step in Australian registration of AstraZeneca COVID-19 antibody cocktails

[ad_1]
(Reuters) – AstraZeneca’s COVID-19 antibody cocktail received its first gesture to register in Australia, the country’s medical regulator said on Tuesday.
The Therapeutic Goods Administration said last week it had given a provisional decision to the Anglo-Swedish pharmaceutical manufacturer to use its antibody cocktail, EVUSHELD, as the first non-vaccine protective shot against COVID-19.
The regulator said the provisional specification is the first step in the process, and added that it now expects AstraZeneca (NASDAQ 🙂 to file a provisional registration application soon.
The specification of antibody-based therapy, which is already being reviewed in real time in Europe and awaiting emergency admission in the United States, comes as Australia raises its vaccination rates, recently launching booster launches, amid easing borders.
A cocktail that has been shown to work as a preventative shot in uninfected people has also been shown to save lives and prevent serious illness when given as a treatment within a week of the first symptoms.
Fusion Media or anyone involved with Fusion Media will not be liable for any loss or damage as a result of relying on the information contained in the data, estimates, charts and buy / sell signals contained on this website. Please be fully informed about the risks and costs associated with trading in the financial markets, which is one of the most risky forms of investment possible.
[ad_2]
Source link